Tarantelli et al. tested the combination of zanubrutinib and selinexor in MCL cell lines to determine if selinexor can increase the efficacy of BTK inhibition by restoring nuclear localization of oncogenic proteins downstream of BCR signaling [40]. The gene discussed is BCR; the disease is mantle cell lymphoma.